Peruvoside

Peruvoside
Clinical data
Other names	(3S,5R,10R,13R,14S,17R)- 3-[(2S,5R)- 3,5-dihydroxy- 4-methoxy- 6-methyloxan- 2-yl]oxy- 14-hydroxy- 13-methyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthrene- 10-carbaldehyde
ATC code	C01AX02 (WHO) ;
Identifiers
	IUPAC name (3β,5β,8ξ,9ξ)- 3-[(6-deoxy- 3-O-methyl- α-D- glycero- hexopyranosyl)oxy]- 14-hydroxy- 19-oxocard- 20(22)enolide;
CAS Number	1182-87-2 ;
PubChem CID	14449;
ChemSpider	16498835 ;
UNII	CT36KGC6A6;
ChEMBL	ChEMBL1075790 ;
CompTox Dashboard (EPA)	DTXSID70881388 ;
ECHA InfoCard	100.013.327
Chemical and physical data
Formula	C30H44O9
Molar mass	548.673 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1OC/C(=C/1)[C@H]6CC[C@@]5(O)[C@]6(C)CC[C@H]3[C@H]5CC[C@@H]4C[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)[C@@H]2O)CC[C@]34C=O;
	InChI InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1 ; Key:PMTSPAGBAFCORP-HBUONDEYSA-N ;
	(what is this?)

Peruvoside (or cannogenin thevetoside) is a cardiac glycoside^[1] for heart failure.^[2]

It is derived from Cascabela thevetia (Thevetia neriifolia).^[2]

References[]

^ Arora RB, Rangaswami S (1972). Peruvoside and Other Cardiotonic Glycoside[s] of Thevetia neriifolia Juss: Chemical, Pharmacological, and Clinical Studies. New Delhi, India: Thomson. LCCN 78900408.
^ ^a ^b Bhatia ML, Manchanda SC, Roy SB (September 1970). "Haemodynamic studies with peruvoside in human congestive heart failure". British Medical Journal. 3 (5725): 740–3. doi:10.1136/bmj.3.5725.740. PMC 1701679. PMID 4919553.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by .